MTF buys 51% of Bone Biologics, Inc.

By

 
Bone Biologics, Inc. announced today it had received another round of investment for preferred shares from the Musculoskeletal Transplant Foundation (MTF). MTF now owns 51% of Bone Biologics. As part of the financing, MTF also provided a line of credit to fund continuing operations.  This financial support continues the investments by MTF that have allowed Bone Biologics, Inc. to progress from research through development of the NELL-1 protein sequence UCB-1 to the current culmination of:

Therapeutic validation in non-human primate trials
Economic manufacturing of cGMP grade product
Patent...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.